The Medicines Company, a biopharmaceutical company, has received the FDA approval for KENGREAL, or cangrelor, as an adjunctive therapy to percutaneous coronary intervention, or PCI, for reducing periprocedural thrombotic events in patients who have ... Individual.com, 1 day ago
Federal Circuit Rules Against The Medicines Company in Angiomax ® (bivalirudin) Patent Litigation - Stockwatch, 1 day ago
MEDICINES : Announces FDA Approval of KENGREAL cangrelor as an Adjunct to Percutaneous Coronary Intervention PCI for Reducing Thrombotic... - 4 Traders, 2 days ago
Wuzhou Zhongheng Group paid $52 million for a 10% stake in Oramed Pharma and China rights to its two diabetes treatments. Oramed, based in Israel, develops oral versions of injected protein drugs. Details of the deal were not disclosed. In December ...Financial Content, 7 hours ago Oramed begins patient enrollment in Phase IIb oral insulin trial of ORMD-0801 Pharmaceutical Business Review, 2 days ago Oramed Pharmaceuticals Inc. (ORMP) Enrolls First Patient In Its Phase Ilb Oral Insulin Study 6/30/2015 ClinicSpace, 3 days ago Oramed Pharmaceuticals submits study protocol to FDA for Phase IIb trial of ORMD-0801 News-Medical.Net, 3 days ago
Zacks cut shares of Trevena (NASDAQ:TRVN) from a buy rating to a hold rating in a research report sent to investors on Friday morning, ARN reports. According to Zacks, Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and ...SleekMoney, 8 hours ago PRA Health Sciences's Hold Rating Reaffirmed at KeyBanc (PRAH) SleekMoney, 12 hours ago Cytokinetics Downgraded by Zacks to Strong Sell (CYTK) SleekMoney, 2 days ago PRA Health Sciences Now Covered by Analysts at KeyBanc (PRAH) SleekMoney, 2 days ago
3-Jul-2015 Finance | Research Spinifex Pharmaceuticals and its Australian subsidiary, Spinifex Pharmaceuticals, a company focused on the development of new drugs for the treatment of chronic pain, has agreed to the sale of Spinifex to ...Manufacturing Chemist, 13 hours ago Novartis to buy pain specialist Spinifex Pharma Field, 4 days ago Spinifex Pharmaceuticals to be acquired by Novartis Center Watch, 4 days ago Novartis shells out $200M-plus for Spinifex and its mid-stage pain drug FiercePharmaMarketing, 4 days ago
Teva Pharmaceutical Industries Ltd., a manufacturer of generic pharmaceuticals, has announced encouraging data from additional analyses of its Phase IIb studies in migraine prevention on efficacy and speed of onset of two distinct doses of ...Individual.com, 13 hours ago Acorda announces encouraging data from Phase IIb Parkinson's disease trial Individual.com, 1 week ago Acorda announces favorable data from Phase IIb Parkinson's disease trial Individual.com, 1 week ago
SteadyMed and Cardiome Enter into a License Agreement for the Commercialization Rights to Trevyent® Outside the U.S.
er, BC, July 3, 2015--(T-Net)--SteadyMed Ltd. (STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs, and Cardiome Pharma Corp. (Nasdaq: ...BC Technology, 14 hours ago
More from: BioSpace, Town Hall...and 35 other sources
Shares of Flexion Therapeutics (NASDAQ:FLXN) have earned an average recommendation of Buy from the eight ratings firms that are presently covering the stock, Analyst Ratings.Net reports . Seven analysts have rated the stock with a buy rating. The ...SleekMoney, 15 hours ago Sarepta Therapeutics Receives Average Recommendation of Buy from Analysts (NASDAQ:SRPT) SleekMoney, 5 days ago
Teva Pharmaceutical Industries Limited ( TEVA - Analyst Report ) and Xenon Pharmaceuticals Inc. ( XENE - Snapshot Report ) reported disappointing top-line results from a phase IIb study on their pain management candidate, TV-45070 (4% and 8% w/w ...Zacks.com, 1 day ago Xenon and Teva's arthritic knee pain drug fails in Phase IIb trial Pharma Letter, 1 day ago Xenon Pharmaceuticals Inc. To Host Conference Call And Webcast Today At 9:00 A.M. Eastern Time To Discuss TV-45070 Phase IIb Study In Osteoarthritis Pain BioSpace, 2 days ago Xenon's Teva-partnered pain drug flunks a test in osteoarthritis FierceBiotech, 2 days ago
More from: , ClinicSpace...and 4 other sources
A number of firms have modified their ratings and price targets on shares of Avalanche Biotechnologies (NASDAQ: AAVL) recently: 7/1/2015 Avalanche Biotechnologies was upgraded by analysts at Zacks from a hold rating to a buy rating. They now ...SleekMoney, 18 hours ago Investment Analysts Weekly Ratings Updates for Avalanche Biotechnologies (AAVL) Ticker Report, 1 week ago Avalanche Bio Downgraded At William Blair, Firm Says Phase IIb 'A Ways Away' Benzinga.com, 2 weeks ago
NOTIFICATION LA PRESENTE ANNONCE N'EST PAS DESTINEE A ETRE COMMUNIQUEE, PUBLIEE OU DISTRIBUEE, DIRECTEMENT OU INDIRECTEMENT, AUX OU VERS LES ETATS-UNIS, L'AUSTRALIE, LE CANADA, LE JAPON OU DANS TOUT AUTRE TERRITOIRE OU UNE TELLE COMMUNICATION ...Sante Log, 1 day ago
on your WebpageAdd Widget >Get your members hooked!